Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1Hepatitis 1Graft vs Host Disease 1Colitis 1Bronchiolitis Obliterans Syndrome 1

Interventions

pembrolizumab 610Carboplatin 376Paclitaxel 283Cisplatin 269Gemcitabine 256Pemetrexed 195Bevacizumab 191Nivolumab 190Docetaxel 190Injections 169Cyclophosphamide 148atezolizumab 138Capecitabine 134Fluorouracil 133Oxaliplatin 132Dexamethasone 129Fulvestrant 115durvalumab 114130-nm albumin-bound paclitaxel 111fludarabine 102Cetuximab 101Leucovorin 97Rituximab 96venetoclax 90Lenalidomide 84Prednisone 79enzalutamide 78Azacitidine 76Irinotecan 74Ipilimumab 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Photopheresis × 1 year × Clear all
NCT07619898 2026-06-02

PHOENIX-ECP

Therakos LLC

Phase 2 Not yet recruiting
112 enrolled
Dermatologic

Colitis, Hepatitis, Melanoma

NCT03112603 2025-08-12

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Incyte Corporation

Phase 3 Completed
330 enrolled 32 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡